Viatris receives FDA approval for RYZUMVI treatment of presbyopia
The company is exploring potential partners in the United States to handle commercialization of this new expanded indication for its ophthalmic solution.
See the latest news and media coverage for Viatris. We track all announcements, press releases, and industry mentions in real time, all in one place.
Global healthcare company
viatris.comLast updated
In short: Viatris agreed to buy Pacira for $1.65B and received FDA approvals for RYZUMVI and Gwyn Lo.
The company is exploring potential partners in the United States to handle commercialization of this new expanded indication for its ophthalmic solution.
Viatris will pay $1.65 billion for non-opioid pain leader Pacira, adding EXPAREL and ZILRETTA. Deal closes end of 2026.
The first-in-class treatment for excessive daytime sleepiness advances the company's portfolio in the region.
The patch offers low-dose estrogen once-weekly contraception with demonstrated efficacy and safety in clinical trials.
Blood pressure medication sold nationwide was recalled due to potential excess drug levels.
Viatris said on Thursday it will buy Pacira Biosciences for $1.65 billion, adding the pain therapy...
Generic drugmaker Viatris has sued Danish pharmaceutical giant Novo Nordisk in Delaware federal court, seeking a ruling that its proposed generic of Novo's blockbuster GLP-1...
Feb. 26 - Viatris: After kicking off an enterprise-wide strategic review a year ago, Viatris plans to cut its global workforce of 32,000 by about...
Track Viatris and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Viatris and other trending companies.